BNP Paribas Financial Markets’s Oramed Pharmaceuticals ORMP Stock Holding History

BNP Paribas Financial Markets’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2	Closed	-$5	–	4177
2023 Q4	$5	Sell	2 -11	-85%	-$23	﹤0.01%	3990
2023 Q3	$34	Buy	+13	New	+$41	﹤0.01%	3875
2023 Q1	–	Sell	-130	Closed	-$1.56K	–	4004
2022 Q4	$1.56K	Buy	130 +1	+0.8%	+$8	﹤0.01%	3760
2022 Q3	$836	Sell	129 -68,221	-100%	-$552K	﹤0.01%	4451
2022 Q2	$313K	Sell	68,350 -6,691	-9%	-$35.8K	﹤0.01%	2898
2022 Q1	$649K	Buy	75,041 +54,775	+270%	+$561K	﹤0.01%	2606
2021 Q4	$289K	Buy	20,266 +14,874	+276%	+$311K	﹤0.01%	3258
2021 Q3	$119K	Buy	5,392 +4,363	+424%	+$74.3K	﹤0.01%	3216
2021 Q2	$13.8K	Buy	+1,029	New	+$11.8K	﹤0.01%	3641

Other funds holding ORMP

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets's ORMP Position: Q1 2024 in Review

BNP Paribas Financial Markets sold out of Oramed Pharmaceuticals (ORMP) in Q1 2024, closing a stake of 2 shares — an estimated $5 sold.

BNP Paribas Financial Markets first reported a position in ORMP in Q2 2021 and held it in 9 quarters. The position peaked at $649K in Q1 2022. 51 funds tracked by Wall St. Rank hold ORMP as of Q1 2024.

BNP Paribas Financial Markets reported no remaining Oramed Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
BNP Paribas Financial Markets sold 2 Oramed Pharmaceuticals shares in Q1 2024, an estimated $5.
BNP Paribas Financial Markets first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 9 quarters.
BNP Paribas Financial Markets's Oramed Pharmaceuticals position peaked at $649K in Q1 2022.
51 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2024.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2024, filed 1 May 2024.